Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
Oral CGRP Inhibitor Is First For Dual Use
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.
You may also be interested in...
Pfizer’s $11.6bn acquisition of the company brings it full rights to the oral migraine drug Nurtec ODT and nasal spray zevegepant, with aims to build a $6bn migraine franchise.
The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer.
As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.